BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioInvent International AB readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies BioInvent International AB's drug
 s run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06205706-2394@assetmemo.bio
DTSTAMP:20261121T005938Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:BI-1910: Phase 1/2 readout est. (NCT06205706)
DESCRIPTION:BI-1910\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: BI-19
 10 as a Single Agent and in Combination With Pembrolizumab for the Treatme
 nt of Advanced Solid Tumors\nEstimated primary completion: 14 July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bi-1910#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06205706
URL:https://assetmemo.bio/drug/bi-1910#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
